Panbela Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBLA research report →
About the company
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer.
- CEO
- Jennifer K. Simpson
- IPO
- 2017
- Employees
- 7
- HQ
- Waconia, MN, US
Price Chart
- Market Cap
- $53.89K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 396.00%
- ROIC
- -10520.48%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,263,000 · 27.68%
- EPS
- $-232429.55 · -470.40%
- Op Income
- $-51,294,000
- FCF YoY
- -58.44%
- 52W High
- $2.50
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 1.88
- Avg Volume
- 1.16K
Get TickerSpark's AI analysis on PBLA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 24 | Nant Capital, LLC | buy | 0 |
| Oct 22, 24 | Nant Capital, LLC | other | 7,702,702 |
| Oct 1, 24 | Horvath Susan | other | 25,480 |
| Oct 1, 24 | Simpson Jennifer K. | other | 72,800 |
| Nov 8, 23 | GOLDMAN SACHS GROUP INC | sell | 72,874 |
| Nov 7, 23 | GOLDMAN SACHS GROUP INC | other | 0 |
| Sep 12, 23 | Jacob Jeffrey E. | other | 275 |
| Mar 27, 23 | Simpson Jennifer K. | other | 99,383 |
| Mar 27, 23 | Horvath Susan | other | 34,369 |
| Mar 27, 23 | Cullen Michael T. | other | 8,333 |
Our PBLA coverage
Recent articles, reports, and earnings notes.
No research on PBLA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBLA report →Similar companies
Peers in the same neighborhood.